Emyria Ltd (AU:EMD)
ASX:EMD
Want to see AU:EMD full AI Analyst Report?
EMD Stock Chart & Stats
AU$0.06
>-AU$0.01(-2.94%)
At close: 4:00 PM EST
AU$0.06
>-AU$0.01(-2.94%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.08
Previous CloseN/A
Volume148.47K
Average Volume (3M)4.06M
Market Cap
AU$45.17M
Enterprise ValueAU$20.91M
Total Cash (Recent Filing)AU$10.50M
Total Debt (Recent Filing)AU$1.06M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,556,500
10 Day Avg. Volume2,903,931
30 Day Avg. Volume4,056,978
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.37
Price to Sales (P/S)9.01
P/FCF Ratio-4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$5.90M
Bulls Say, Bears Say
Bulls Say
Specialist Clinical + Research FocusA combined specialist-clinic and clinical-research model creates durable demand exposure: ongoing patient care revenue from clinics plus long-term research capabilities. This vertical focus on mental health and neuropsychiatry supports repeat clinical referrals, trial site expertise, and credibility with sponsors over months.
Diversified Revenue MixHaving both clinical services and research-related income provides structural diversification. Patient-facing services generate recurring fee-for-service cash flows, while trial and research fees can provide episodic sponsor payments and partnerships, reducing single-source dependency and smoothing revenue variability over time.
Low Leverage / Equity-backed Balance SheetA low debt-to-equity ratio indicates limited leverage and lower fixed financial burden, preserving capacity to fund trials or expand clinics without heavy interest expense. The relatively healthy equity financing mix gives managerial flexibility to raise capital or absorb short-term losses without acute solvency risk.
Bears Say
Declining RevenueA >20% revenue decline is a durable signal of weakening demand, execution issues, or reduced trial activity. Over a 2-6 month horizon this constrains reinvestment in clinics and research, reduces negotiating leverage with sponsors, and makes it harder to restore scale without new commercial or partnership wins.
Persistent Negative MarginsSustained negative gross and operating margins indicate the business is not yet structurally profitable. This erodes equity and means ongoing operations rely on funding rather than internal cash generation, limiting the company's ability to invest in growth, hire talent, or commercialize research outputs.
Negative Operating And Free Cash FlowPersistent cash flow deficits force reliance on external financing and reduce strategic optionality. Even with high free cash flow growth rates noted, ongoing negative OCF and FCF undermine runway for trials and clinic operations, increasing risk that funding cycles, not operations, will dictate near-term strategy.
Emyria Ltd News
EMD FAQ
What was Emyria Ltd’s price range in the past 12 months?
Emyria Ltd lowest share price was AU$0.02 and its highest was AU$0.08 in the past 12 months.
What is Emyria Ltd’s market cap?
Emyria Ltd’s market cap is AU$45.17M.
When is Emyria Ltd’s upcoming earnings report date?
Emyria Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 129 days.
How were Emyria Ltd’s earnings last quarter?
Emyria Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Emyria Ltd overvalued?
According to Wall Street analysts Emyria Ltd’s price is currently Overvalued.
Does Emyria Ltd pay dividends?
Emyria Ltd does not currently pay dividends.
What is Emyria Ltd’s EPS estimate?
Emyria Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emyria Ltd have?
Emyria Ltd has 806,556,500 shares outstanding.
What happened to Emyria Ltd’s price movement after its last earnings report?
Emyria Ltd reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.704%.
Which hedge fund is a major shareholder of Emyria Ltd?
Currently, no hedge funds are holding shares in AU:EMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emyria Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EMD Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.66%
12-Months-Change
Fundamentals
Return on Equity
-52.26%
Trailing 12-Months
Asset Growth
170.82%
Trailing 12-Months
Company Description
Emyria Ltd
Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops cannabinoid-based medicines, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and irritable bowel syndrome; and EMD-RX7 for multiple medical conditions. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
Technical Analysis
Options Prices
Currently, No data available
---